OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals

MONSEY, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of Opiant Pharmaceuticals, Inc. OPNT ("Opiant") acted in the best interests of Opiant shareholders in approving the sale of Opiant to Indivior for $20.00 per share in cash, plus a contingent value right (CVR) worth up to $8.00 per share.

If you remain an Opiant shareholder and have questions about your legal rights, you may contact our firm at the following link to discuss your options at no charge:

https://wohlfruchter.com/cases/opiant-pharmaceuticals/

Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com.

Why is there an investigation?
On November 14, 2022, Opiant announced that it had agreed to be acquired by Indivior for $20.00 per share in cash, plus up to $8 per share in contingent value rights (CVRs) that may become payable in the event that certain net revenue milestones are achieved by Opiant's lead asset OPNT003, during a relevant seven-year period.

The agreement has been approved by the Opiant board of directors ("Board").

Our investigation concerns whether Opiant's Board acted in the best interests of Opiant shareholders in approving the sale, including whether the acquisition price adequately compensates Opiant shareholders, and whether all material information regarding the transaction has been fully disclosed.

Notably, according to an analysis of Wall Street price targets for Opiant in the last 90 days published on Seeking Alpha, there is an average price target of $40.25 per share, which is above the deal price.

About Wohl & Fruchter
Wohl & Fruchter LLP, with offices in New York City and Monsey, has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
alerts@wohlfruchter.com
www.wohlfruchter.com


Posted In: NewsLegalPress Releases